432 related articles for article (PubMed ID: 26758290)
1. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
Chan A; de Seze J; Comabella M
CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Miller AE
Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
4. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
6. Teriflunomide in multiple sclerosis: an update.
Miller AE
Neurodegener Dis Manag; 2017 Feb; 7(1):9-29. PubMed ID: 27937746
[TBL] [Abstract][Full Text] [Related]
7. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
8. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
Miller AE; O'Connor P; Wolinsky JS; Confavreux C; Kappos L; Olsson TP; Truffinet P; Wang L; D'Castro L; Comi G; Freedman MS;
Mult Scler; 2012 Nov; 18(11):1625-32. PubMed ID: 22723573
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P; Comi G; Freedman MS; Miller AE; Kappos L; Bouchard JP; Lebrun-Frenay C; Mares J; Benamor M; Thangavelu K; Liang J; Truffinet P; Lawson VJ; Wolinsky JS;
Neurology; 2016 Mar; 86(10):920-30. PubMed ID: 26865517
[TBL] [Abstract][Full Text] [Related]
10. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
[TBL] [Abstract][Full Text] [Related]
11. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
Brunetti L; Wagner ML; Maroney M; Ryan M
Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
Freedman MS; Wolinsky JS; Wamil B; Confavreux C; Comi G; Kappos L; Olsson TP; Miller A; Benzerdjeb H; Li H; Simonson C; O'Connor PW;
Neurology; 2012 Jun; 78(23):1877-85. PubMed ID: 22622860
[TBL] [Abstract][Full Text] [Related]
13. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
Bencsik K; Rózsa C; Vécsei L
Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
Sartori A; Carle D; Freedman MS
Expert Opin Pharmacother; 2014 May; 15(7):1019-27. PubMed ID: 24742277
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide for the treatment of multiple sclerosis.
Warnke C; Stüve O; Kieseier BC
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
[TBL] [Abstract][Full Text] [Related]
16. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
Scott LJ
Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
[TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
18. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS;
N Engl J Med; 2011 Oct; 365(14):1293-303. PubMed ID: 21991951
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
Wolinsky JS; Narayana PA; Nelson F; Datta S; O'Connor P; Confavreux C; Comi G; Kappos L; Olsson TP; Truffinet P; Wang L; Miller A; Freedman MS;
Mult Scler; 2013 Sep; 19(10):1310-9. PubMed ID: 23447359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
